- Home
- NVO
NVO
Novo Nordisk A/S
as 12-20-2024 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 530.0B | IPO Year: | N/A |
| Target Price: | $144.20 | AVG Volume (30 days): | 7.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.17 | EPS Growth: | 26.84 |
| 52 Week Low/High: | $81.50 - $148.15 | Next Earning Date: | 02-05-2025 |
| Revenue: | $40,469,178,712 | Revenue Growth: | 26.15% |
| Revenue Growth (this year): | 25.02% | Revenue Growth (next year): | 20.47% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
TipRanks
6 hours ago
Novo obesity data positive for Eli Lilly and Amgen, says UBS
TipRanks
6 hours ago
Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data
TipRanks
6 hours ago
Weight loss seen with Novo’s CagriSema weaker than expected, says BofA
Motley Fool
7 hours ago
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Motley Fool
9 hours ago
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Morningstar Research
17 hours ago
Analyst Report: Novo Nordisk A/S
Investor's Business Daily
21 hours ago
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.
Investor's Business Daily
21 hours ago
Stock Market Today: Dow Jones, Other Indexes Rebound But Trim Gains; Nvidia Climbs After Bullish Report (Live Coverage)
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.